And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

NBRV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.63%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Nabriva Therapeutics Insider Trading History Chart

Nabriva Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/22/2024 01:00 AM ET

Days: 30 | 90 | 365

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Nabriva Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2022	Charles A Rowland Jr	Director	Sell	8,496	$0.17	$1,444.32	15,277
12/28/2021	Theodore R Schroeder	CEO	Buy	100,000	$0.57	$57,000.00
12/27/2021	J. Christopher Naftzger	General Counsel	Buy	7,000	$0.59	$4,130.00
9/14/2021	Theodore R. Schroeder	CEO	Buy	50,000	$1.13	$56,500.00	226,875
8/2/2021	Stephen W. Webster	Director	Sell	777	$1.20	$932.40	18,473

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for Nabriva Therapeutics (NASDAQ:NBRV)

0.27% of Nabriva Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Nabriva Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2023	Susquehanna International Group LLP	22,294	$41K	0.0%	N/A	0.073%
12/2/2022	Values First Advisors Inc.	25,891	$54K	0.0%	-40.8%	0.085%
5/16/2022	Frazier Life Sciences Management L.P.	425,650	$0.18M	0.0%	N/A	0.070%
2/14/2022	GSA Capital Partners LLP	357,481	$0.21M	0.0%	N/A	0.066%
11/16/2021	Two Sigma Securities LLC	39,936	$48K	0.0%	N/A	0.007%
11/5/2021	Advisor Group Holdings Inc.	26,500	$32K	0.0%	+5,200.0%	0.005%
9/3/2021	Parametric Portfolio Associates LLC	41,079	$55K	0.0%	+144.8%	0.008%
8/16/2021	State Street Corp	183,336	$0.25M	0.0%	+70.6%	0.037%
8/13/2021	Renaissance Technologies LLC	869,390	$1.17M	0.0%	+665.3%	0.176%
8/1/2021	Clear Creek Financial Management LLC	20,050	$27K	0.0%	N/A	0.004%
5/19/2021	Virtu Financial LLC	31,186	$52K	0.0%	+41.4%	0.009%
5/19/2021	Squarepoint Ops LLC	156,623	$0.26M	0.0%	N/A	0.044%
5/18/2021	Jane Street Group LLC	47,061	$78K	0.0%	N/A	0.019%
5/14/2021	Dimensional Fund Advisors LP	35,302	$59K	0.0%	+67.2%	0.014%
5/13/2021	Renaissance Technologies LLC	113,601	$0.19M	0.0%	-66.8%	0.045%
3/8/2021	Dimensional Fund Advisors LP	21,112	$51K	0.0%	-91.5%	0.014%
2/25/2021	Dimensional Fund Advisors LP	21,112	$51K	0.0%	-91.5%	0.014%
2/24/2021	Virtu Financial LLC	22,060	$53K	0.0%	N/A	0.015%
2/13/2021	Clear Creek Financial Management LLC	20,050	$48K	0.0%	N/A	0.013%
2/11/2021	Frazier Management LLC	425,650	$1.03M	0.1%	-90.0%	0.282%
2/10/2021	Renaissance Technologies LLC	342,360	$0.83M	0.0%	+1,025.0%	0.227%
2/9/2021	Wells Fargo & Company MN	14,464	$35K	0.0%	-92.8%	0.010%
2/5/2021	Aisling Capital Management LP	191,028	$0.46M	0.1%	-90.0%	0.127%
2/4/2021	GSA Capital Partners LLP	50,549	$0.12M	0.0%	N/A	0.034%
1/21/2021	Kestra Private Wealth Services LLC	35,174	$88K	0.0%	-94.5%	0.023%
11/13/2020	Morgan Stanley	361,377	$0.19M	0.0%	-13.3%	0.018%
11/9/2020	Kestra Private Wealth Services LLC	643,800	$0.34M	0.0%	N/A	0.033%
10/30/2020	WINTON GROUP Ltd	633,831	$0.34M	0.0%	+72.4%	0.032%
10/8/2020	Exane Derivatives	134,886	$72K	0.0%	+22.5%	0.007%
10/6/2020	Exane Derivatives	134,886	$72K	0.0%	+22.5%	0.007%
8/14/2020	Bank of America Corp DE	55,096	$37K	0.0%	-32.5%	0.004%
8/13/2020	FMR LLC	14,292,619	$9.64M	0.0%	+134.2%	0.994%
8/12/2020	Hudson Bay Capital Management LP	5,453,396	$54K	0.0%	N/A	0.381%
8/7/2020	Virtu Financial LLC	62,115	$42K	0.0%	N/A	0.004%
8/5/2020	WINTON GROUP Ltd	367,665	$0.25M	0.0%	N/A	0.026%
7/30/2020	Integrated Wealth Concepts LLC	196,224	$0.13M	0.0%	N/A	0.014%
7/16/2020	Clear Creek Financial Management LLC	290,000	$0.20M	0.1%	+158.9%	0.020%
7/10/2020	Exane Derivatives	110,078	$74K	0.0%	+34.1%	0.008%
5/18/2020	Vivo Capital LLC	1,704,130	$0.98M	0.1%	N/A	0.180%
5/15/2020	Sabby Management LLC	367,613	$0.21M	0.1%	-64.5%	0.039%
5/15/2020	Morgan Stanley	335,215	$0.19M	0.0%	-18.0%	0.035%
5/15/2020	Rock Springs Capital Management LP	1,050,000	$0.60M	0.0%	-50.0%	0.111%
5/14/2020	Wells Fargo & Company MN	110,493	$64K	0.0%	+28.4%	0.012%

Data available starting January 2016

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: N/A

50 Day Range

MA: $0.14

$0.00

$0.52

52 Week Range

Now: N/A

Volume

N/A

Average Volume

29,344 shs

Market Capitalization

$45.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Who are the company insiders with the largest holdings of Nabriva Therapeutics?: Nabriva Therapeutics' top insider investors include:
Charles A Rowland Jr (Director)
Learn More about top insider investors at Nabriva Therapeutics.

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here